Momenta Pharmaceuticals, Inc. (MNTA)

[tinkershaw]

A 4th Q launch leaves ample time for the filing of the lawsuit. At this point, MNTA has to file if they have anything. And given the history of such suits in pharma, as evidenced by Teva, such suits don't usually need a lot to go on to gain some traction and reality, if for nothing else to buy traction at the rate of over $50 million per quarter for MNTA alone.

Such suit will be filed as I believe the most likely explanation for Ampha's approval is use of MNTA IP.

No, investing in IP is not a fun thing to do however. Neither is investing in lawsuits. Now a copaxone approval....yes, well, life is not always so kind.

Tinker